Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Operating Expenses: 2011-2025

Historic Other Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Sep 2025 value amounting to $5,000.

  • Lineage Cell Therapeutics' Other Operating Expenses fell 86.84% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 4219.20%. This contributed to the annual value of $334,000 for FY2024, which is 50.22% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Other Operating Expenses of $5,000 as of Q3 2025, which was down 99.97% from $14.9 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Operating Expenses peaked at $14.9 million during Q2 2025, and registered a low of $5,000 during Q3 2025.
  • Over the past 3 years, Lineage Cell Therapeutics' median Other Operating Expenses value was $108,500 (recorded in 2023), while the average stood at $1.6 million.
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Other Operating Expenses showed a top increase of 33,715.91% in 2025 and a maximum decrease of 86.84% in 2025.
  • Over the past 3 years, Lineage Cell Therapeutics' Other Operating Expenses (Quarterly) stood at $169,000 in 2023, then slumped by 77.51% to $154,000 in 2024, then slumped by 86.84% to $5,000 in 2025.
  • Its Other Operating Expenses stands at $5,000 for Q3 2025, versus $14.9 million for Q2 2025 and $36,000 for Q1 2025.